Recently, General Electric (NYSE:GE), Zimmer Biomet (NYSE: ZBH) and Toshiba (TYO:6502) announced their plans to slim down by spinning out core businesses. Now, Johnson & Johnson (NYSE:JNJ) is following a similar approach by making its consumer health business a standalone company.
J&J will retain its pharmaceutical and medical device segments.
The company said in an announcement that it made the decision to boost operational performance and strategic flexibility.
Get the full story from our sister site, Pharmaceutical Processing World.